The drug-device combination will be marketed in the UK under Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda)

Biocon has launched GLP-1 peptide, Liraglutide, for diabetes and obesity, in the UK. The drug-device combination will be marketed in the UK under Liraglutide Biocon for diabetes (gVictoza) and Biolide for chronic weight management (gSaxenda).

The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, earlier this year, making Biocon Limited the first generics company to obtain approval for gLiraglutide in a major regulated market.

Siddharth Mittal, CEO and MD, Biocon, said, “The launch of our gLiraglutide for diabetes and obesity in the UK marks a significant milestone for Biocon. Making this GLP-1 peptide more accessible and affordable to patients dealing with these conditions is a testament to our unwavering commitment to enhancing healthcare outcomes across the globe. The timely launch will offer healthcare providers and patients affordable access to this drug and help fulfil an unmet need. The launch also underpins Biocon’s scientific and manufacturing capabilities in developing and bringing to market complex, vertically integrated, GLP-1 formulations. We will continue to focus our efforts towards expanding the reach of gLiraglutide into other European markets, the US and select MoW geographies, and enhancing our pipeline of GLP-1 peptide products.”